Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5: is it significant?
- 1 Downloads
To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5.
We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug.
Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4.
Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.
KeywordsChronic kidney disease Lactic acidosis Metformin Type 2 diabetes mellitus
This study was funded through a seed grant from Manipal Academy of Higher Education, India.
RAP: study concept and design, ASM: acquisition of data, SPN and DR: preparation of manuscript, VG: statistical analysis. All authors contributed to the preparation of the report and approved the final version. We have included a conflict of interest disclosure statement in the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Statement of ethics
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Powers AC, Niswender KD, Rickels MR. Diabetes Mellitus: Management and Therapies. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds) Harrison’s Principles of Internal Medicine, 20e New York, NY: McGraw-Hill. http://accessmedicine.mhmedical.com.kmcezproxy.manipal.edu/content.aspx?Bookid=2129§ionid=192288412. Accessed 01 Nov 2018
- 4.Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States. Website. http://www.cdc.gov/ckd. Accessed 6 Nov 2018